TBPH
Theravance Biopharma Inc
17.00$
+0.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +11.9% | -17.4% | -1.7% | +18.3% | +11.2% | -17.9% | +70.2% | -23.7% | +129.6% | -61.4% | +17.1% | – | |
| – | +520.8% | +7.9% | +11.0% | -6.9% | +2.0% | +21.1% | -8.4% | -22.7% | -81.4% | -4.6% | +0.4% | – | |
| – | -35.5% | -40.2% | -22.3% | +76.7% | +22.4% | -57.7% | +299.0% | -24.4% | +273.7% | -60.1% | +9.0% | – | |
| – | +14.2% | -0.3% | +11.0% | -6.9% | +1.2% | +22.2% | -8.4% | -22.7% | -14.2% | -16.3% | -19.2% | – | |
| – | -33.4% | +55.8% | +1.9% | -1.1% | -15.8% | +29.4% | +0.3% | -0.5% | +1.0% | -4.3% | -20.0% | – | |
| – | -33.0% | +8.1% | +19.5% | -7.8% | +0.3% | -0.7% | +0.3% | -0.5% | +46.3% | -12.2% | -15.5% | – | |
| – | – | – | – | – | – | – | – | – | – | -133.3% | – | – | |
| – | +2.3% | +1.0% | +2.4% | -2.2% | +2.1% | +0.0% | +3.1% | -13.6% | +1.7% | -100.0% | – | – | |
| – | – | – | – | – | – | – | – | -103.9% | – | -108.9% | – | – | |
| – | +155.6% | -63.9% | +3.6% | +102.3% | +149.0% | -108.5% | – | -135.4% | – | -112.8% | – | – | |
| – | – | – | – | – | – | – | – | -93.4% | +1,588.1% | -108.1% | – | – | |
| – | – | – | – | – | – | – | – | -102.6% | – | -107.5% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.